Natoli and the Council for Responsible Nutrition (CRN) recently revealed upcoming events that will benefit the industry, while Gnosis reviewed a successful conference held earlier this month.
The Natoli Institute for Industrial Pharmaceutical Research and Development will hold its inaugural tableting course, The Tablet Manufacturing Process, Aug. 16 to 19, 2015. The course offers a hands-on experience with the tablet manufacturing process, from formulation development to tablet design to tablet compression, all presented in a lab at the Arnold and Marie Schwartz College of Pharmacy and Health Sciences on the Brooklyn campus of Long Island University. Academic and industrial experts will cover powder preparation techniques and the science behind best practices that will help participants overcome a wide array of tableting challenges. Key areas of concentration include understanding powder characterization and its effect on tablet compression, excipient selection, formulation development, hot melt extrusion and the science of tablet press operation.
Later this fall, CRN will present key regulatory officials from FDA and FTC as featured speakers during its annual symposium for the dietary supplement industry, The Conference, which will take place Oct. 21 to 24 , 2015, in Palm Springs, California. FDA’s Ted Elkin, director of the agency’s office of analytics and outreach, will discuss the role of the Center for Food Safety and Applied Nutrition (CFSAN) in assuring that the dietary supplement and functional food products on the market are safe for consumers, and that these products provide the health benefits that are claimed on their labels. FTC’s Mary K. Engle, associate director of the division of advertising Practices, will discuss the commission’s role in policing potential untruthful, misleading or unsubstantiated consumer advertising, particularly related to health benefit claims for dietary supplements and functional foods. Both speakers will address attendees during the morning of the first full day of The Conference (Thursday, Oct. 22). For more information or to register, visit www.crnusa.org/2015events .
Gnosis recently sponsored the FASEB (Federation of American Societies for Experimental Biology) Conference on Vitamin K, which took place earlier this month in Itasca, Illinois. According to Gnosis, the conference provided opportunities to discuss research on Vitamin K, scientific updates and new directions for future applications. The longstanding conference focused on emerging aspects of vitamin K biochemistry, current research on Vitamin K metabolism and new developments in emerging roles for vitamin K-dependent proteins for managing clinical conditions such as CVD, osteoarthritis and chronic kidney disease.